BPC-157 and TB-500 for elbow tendonitis: hype vs. human data

What did @strandstrong actually say?

The creator walked through reconstituting a combined BPC-157 and TB-500 product called "Wolverine stock" using bacteriostatic water, then said they plan to inject "500 micrograms of each" daily to heal their tendons. They presented this as a straightforward protocol, not a speculative one.

To be clear about what was shown: one milliliter of bacteriostatic water added to a single vial, producing 10 doses at 500 mcg per peptide per dose. The creator described daily subcutaneous injection near the injury site. No mention of a prescribing physician, no mention of regulatory status, and no acknowledgment that these compounds are not approved for human use by the FDA.

Does the science back this up?

The honest answer is: maybe, in animals. The human evidence is thin, and calling this a proven "protocol" is getting ahead of the data by a significant margin.

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Animal studies, primarily in rats, have shown accelerated tendon-to-bone healing and reduced inflammation. Chang et al. (2011, Journal of Applied Physiology) found improved Achilles tendon healing in rodents with BPC-157 injections. TB-500 is a synthetic fragment of thymosin beta-4, which has shown roles in actin regulation and tissue repair in preclinical models. Goldstein et al. (2012, Annals of the New York Academy of Sciences) reviewed thymosin beta-4's regenerative properties, again largely in animal models. Neither compound has completed Phase 3 clinical trials in humans for tendon repair. Extrapolating rat tendon data to a human elbow is a real scientific leap, and anyone presenting this as a settled protocol should say so upfront.

What did they get wrong, and what did they get right?

The reconstitution technique itself is largely correct. Using bacteriostatic water rather than sterile water is the right call for a multi-dose vial since benzyl alcohol inhibits bacterial growth. Swirling rather than shaking a peptide vial is also appropriate since aggressive agitation can degrade the compound. Credit where it is due.

What they got wrong, or at least glossed over entirely: these are not regulated pharmaceutical products. Compounded or research-grade peptides sold as "Wolverine stock" have no guaranteed purity, sterility, or accurate concentration. A 2022 study by Cohen et al. (JAMA Internal Medicine) analyzed 10 BPC-157 products and found significant variability in actual peptide content versus labeled amounts. One product contained less than 10 percent of its stated dose. Injecting an unverified compound into a tendon-adjacent area carries real infection and dosing risks that were completely absent from this video.

Calling a daily 500 mcg injection schedule a settled "protocol" for tendon healing also overstates what the evidence supports. There is no established human dosing protocol because no human trials have established one.

What should you actually know?

If you have elbow tendinopathy, there are evidence-based options that do not involve self-injecting unregulated peptides. Eccentric loading programs, as studied by Alfredson et al. (1998, American Journal of Sports Medicine), remain among the best-supported interventions for tendinopathy. Platelet-rich plasma injections have a mixed but more substantial human evidence base than BPC-157.

That does not mean BPC-157 and TB-500 are worthless. The preclinical data is genuinely interesting, and there are researchers actively investigating these compounds. But "interesting preclinical data" and "daily self-injection protocol" are very different things. Anyone considering peptide therapy should do so under the supervision of a licensed provider who can assess purity sourcing, contraindications, and whether the intervention makes sense for their specific injury. The DIY framing in this video, with no caveats and no clinical oversight mentioned, sets a poor example for the people watching it.